REPL INVESTOR NOTICE: Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead the Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

SAN DIEGO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026, inclusive (the “Class Period”), have until October 5, 2026 to seek appointment as lead plaintiff of the Replimune class action lawsuit. Captioned Toor v.

GlobeNewsWire • 3 hours ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL

NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

GlobeNewsWire • 16 hours ago

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

GlobeNewsWire • a day ago

Replimune Group, Inc. (REPL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES, Aug. 11, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Replimune Group, Inc. (REPL) have opportunity to lead the securities fraud class action lawsuit.

PRNewsWire • 20 hours ago

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - August 11, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Replimune securities between October 20, 2025 and April 10, 2026, both dates inclusive (the "Class Period").

Newsfile Corp • a day ago

REPL INVESTOR ALERT: Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead the Replimune Class Action Lawsuit

SAN DIEGO, Aug. 10, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP  announces that purchasers or acquirers of Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026, inclusive (the "Class Period"), have until October 5, 2026 to seek appointment as lead plaintiff of the Replimune class action lawsuit.  Captioned Toor v.

PRNewsWire • Aug 10, 2026

REPL INVESTOR ALERT: Securities Class Action Filed Against Replimune Group, Inc. – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)---- $REPL #ClassAction--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) common stock between October 20, 2025 and April 10, 2026, inclusive (“the Class Period”). If you suffered a loss on your Replimune investments, you have until October 5, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted afte.

Business Wire • Aug 11, 2026

REPL Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Replimune Group, Inc.

SAN DIEGO, Aug. 10, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026 ("Class Period").  Replimune purports to be a clinical-stage biotechnology company focused on novel oncolytic immunotherapies.

PRNewsWire • Aug 10, 2026

Replimune Announces Pricing of $150 Million Underwritten Offering

BOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL) (“Replimune”), a commercial-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the pricing of an underwritten offering of 9,701,490 shares of its common stock at an offering price of $12.06 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,736,340 shares of its common stock at a purchase price of $12.0599 per pre-funded warrant, which equals the offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds from the offering are expected to be approximately $150 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities in the offering are to be sold by Replimune. The offering is expected to close on August 11, 2026, subject to the satisfaction of customary closing conditions.

GlobeNewsWire • Aug 10, 2026

Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months

REPL's RP1 secures FDA approval for advanced melanoma, easing regulatory uncertainty. The company expands its oncolytic immunotherapy pipeline.

Zacks Investment Research • Aug 10, 2026